The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

Introduction Probiotics may benefit irritable bowel syndrome (IBS) symptoms, but randomised controlled trials (RCTs) have been conflicting; therefore a systematic review was conducted. Methods MEDLINE (1966 to May 2008), EMBASE (1988 to May 2008) and the Cochrane Controlled Trials Register (2008) electronic databases were searched, as were abstracts from DDW (Digestive Diseases Week) and UEGW (United European Gastroenterology Week), and authors were contacted for extra information. Only parallel group RCTs with at least 1 week of treatment comparing probiotics with placebo or no treatment in adults with IBS according to any acceptable definition were included. Studies had to provide improvement in abdominal pain or global IBS symptoms as an outcome. Eligibility assessment and data extraction were performed by two independent researchers. Data were synthesised using relative risk (RR) of symptoms not improving for dichotomous data and standardised mean difference (SMD) for continuous data using random effects models. Results 19 RCTs (18 papers) in 1650 patients with IBS were identified. Trial quality was generally good, with nine reporting adequate methods of randomisation and six a method of concealment of allocation. There were 10 RCTs involving 918 patients providing outcomes as a dichotomous variable. Probiotics were statistically significantly better than placebo (RR of IBS not improving=0.71; 95% CI 0.57 to 0.88) with a number needed to treat (NNT)=4 (95% CI 3 to 12.5). There was significant heterogeneity (χ2=28.3, p=0.001, I2=68%) and possible funnel plot asymmetry. Fifteen trials assessing 1351 patients reported on improvement in IBS score as a continuous outcome (SMD=−0.34; 95% CI −0.60 to −0.07). There was statistically significant heterogeneity (χ2=67.04, p<0.001, I2=79%), but this was explained by one outlying trial. Conclusion Probiotics appear to be efficacious in IBS, but the magnitude of benefit and the most effective species and strain are uncertain.

[1]  J. Corander,et al.  The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. , 2007, Gastroenterology.

[2]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[3]  M. Färkkilä,et al.  A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6‐month intervention , 2005, Alimentary pharmacology & therapeutics.

[4]  N. Vaisman,et al.  The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study. , 2005, Clinical nutrition.

[5]  A. Palva,et al.  Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR , 2005, The American Journal of Gastroenterology.

[6]  W. Jackson,et al.  Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice , 2005, Gut.

[7]  E. Quigley.  Disturbances of motility and visceral hypersensitivity in irritable bowel syndrome: biological markers or epiphenomenon. , 2005, Gastroenterology clinics of North America.

[8]  J. Bienenstock,et al.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats , 2005, Gut.

[9]  S. Collins.  Is the irritable gut an inflamed gut? , 1992, Scandinavian journal of gastroenterology. Supplement.

[10]  C. Neut,et al.  YOGHURT WITH BIFIDOBACTERIUM LONGUM REDUCES ERYTHROMYCIN-INDUCED GASTROINTESTINAL EFFECTS , 1987, The Lancet.

[11]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating , 2005, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[12]  N. D. de Wit,et al.  Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. , 2005, The Cochrane database of systematic reviews.

[13]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[14]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[15]  B. Flourié,et al.  Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date , 2007, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[16]  D. Chang,et al.  Therapeutic Effect of Lactobacillus acidophilus-SDC 2012, 2013 in Patients with Irritable Bowel Syndrome , 2008, Digestive Diseases and Sciences.

[17]  A. Zinsmeister,et al.  A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea‐predominant irritable bowel syndrome , 2003, Alimentary pharmacology & therapeutics.

[18]  M. Camilleri,et al.  Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials , 2003, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[19]  M. Farthing,et al.  Lactobacilli to prevent traveler's diarrhea? , 1995, The New England journal of medicine.

[20]  B. Birkenfeld,et al.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome , 2001, European journal of gastroenterology & hepatology.

[21]  D. Ardid,et al.  Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors , 2007, Nature Medicine.

[22]  S. Allen,et al.  Probiotics for treating infectious diarrhoea. , 2003, The Cochrane database of systematic reviews.

[23]  G. Bergonzelli,et al.  Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. , 2004, Gastroenterology.

[24]  P. Whorwell,et al.  Efficacy of an Encapsulated Probiotic Bifidobacterium infantis 35624 in Women with Irritable Bowel Syndrome , 2006, The American Journal of Gastroenterology.

[25]  P. Whorwell,et al.  Tegaserod for the treatment of irritable bowel syndrome. , 2004, The Cochrane database of systematic reviews.

[26]  S. Ahrné,et al.  Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[27]  X. Dray,et al.  A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. , 2008, Gastroenterologie clinique et biologique.

[28]  A. Garg,et al.  GASTROENTEROLOGY 2006;131:445–450 Incidence and Epidemiology of Irritable Bowel Syndrome After a Large Waterborne Outbreak of Bacterial Dysentery , 2022 .

[29]  O. Chassany,et al.  Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial , 2007, Alimentary pharmacology & therapeutics.

[30]  V. Théodorou,et al.  Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction , 2005, Gut.

[31]  K. McCoy,et al.  Immune responses that adapt the intestinal mucosa to commensal intestinal bacteria , 2005, Immunology.

[32]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[33]  M. Thabane,et al.  Systematic review and meta‐analysis: the incidence and prognosis of post‐infectious irritable bowel syndrome , 2007, Alimentary pharmacology & therapeutics.

[34]  Yu Yang,et al.  [Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type]. , 2006, Zhongguo zhen jiu = Chinese acupuncture & moxibustion.

[35]  E. Quigley.  The efficacy of probiotics in IBS. , 2008, Journal of clinical gastroenterology.

[36]  F. Marotta,et al.  Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. , 2004, Chinese journal of digestive diseases.

[37]  F. Shanahan.  Irritable bowel syndrome: shifting the focus toward the gut microbiota. , 2007, Gastroenterology.

[38]  M. Saxelin,et al.  Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea. , 1990, Annals of medicine.

[39]  K W Heaton,et al.  Functional bowel disorders and functional abdominal pain , 1999, Gut.

[40]  E. Zoetendal,et al.  Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota , 2007, Alimentary pharmacology & therapeutics.

[41]  Hyojin Park,et al.  [The effects of probiotics on symptoms of irritable bowel syndrome]. , 2006, The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.

[42]  P. Thorn,et al.  Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. , 1989, Scandinavian journal of primary health care.